RxDoctor Payments Data

Catherine Suriano, MD

Family Medicine · Coeur D Alene, IDNPI 1255441135

Payments from drug & device makers

$590in general payments, 2019–2025

Across 27 payments — averaging $21.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$245
  • Johnson & Johnson$155
  • Novo Nordisk$41
  • GSK$30
  • Lilly USA, LLC$22
  • Exact Sciences$21
  • plus $76 from 5 others

What the payments were for

  • Food & beverage$57698%
  • Education$142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$590 in reported general payments places this provider in the 65th percentile of 803 family medicine providers in Idaho.

See all family medicine providers in Idaho

Medicare billing

Part B allowed, 2024
$86,755
Medicare patients
387
Services billed
1,117

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban98$79,066
OzempicSemaglutide58$59,693
TrulicityDulaglutide36$31,832
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$30,680
JardianceEmpagliflozin19$17,982
XareltoRivaroxaban14$17,548
JanuviaSitagliptin Phosphate24$16,127
EntrestoSacubitril/Valsartan16$14,256
Stiolto RespimatTiotropium Br/Olodaterol Hcl16$11,014
Emgality PenGalcanezumab-Gnlm12$8,635
Rosuvastatin Calcium364$6,608
Aripiprazole75$6,405
Atorvastatin Calcium429$4,887
Levothyroxine Sodium606$4,659
SynthroidLevothyroxine Sodium109$4,221

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$41$59,69358 claims
Lilly USA, LLCTrulicity$22$31,83236 claims
GSKTrelegy Ellipta$30$30,68041 claims
Johnson & JohnsonXarelto$155$17,54814 claims
AbbVieSynthroid$14$4,221109 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 803 family medicine providers in Idaho.

Other family medicine in Coeur D Alene

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →